Aims: The objective of the present study was to investigate the relationship between extremely low-frequency magnetic field (ELF-MF) exposure and mortality from several neurodegenerative conditions in Swiss railway employees. Methods: We studied a cohort of 20,141 Swiss railway employees with 464,129 person-years of follow-up between 1972 and 2002. For each individual, cumulative exposure was calculated from on-site measurements and modelling of past exposure. We compared cause-specific mortality in highly exposed train drivers (mean exposure: 21 µT) with less exposed occupational groups (for example station masters: 1 µT). Results: The hazard ratio for train drivers compared to station masters was 1.96 [95% confidence interval (CI) = 0.98–3.92] for senile dementia and 3.15 (95% CI = 0.90–11.04) for Alzheimer’s disease. For every 10 µT years of cumulative exposure senile dementia mortality increased by 5.7% (95% CI = 1.3–10.4), Alzheimer’s disease by 9.4% (95% CI = 2.7–16.4) and amyotrophic lateral sclerosis by 2.1% (95% CI = –6.8 to 11.7). There was no evidence for an increase in mortality from Parkinson’s disease and multiple sclerosis. Conclusions: This study suggests a link between exposure to ELF-MF and Alzheimer’s disease and indicates that ELF-MF might act in later stages of the disease process.

Keywords:
Electromagnetic fields, Neurodegenerative diseases, Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Occupational exposure
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.